Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Language
Publication year range
1.
Clin Immunol ; 212: 108346, 2020 03.
Article in English | MEDLINE | ID: mdl-31954803

ABSTRACT

Previous studies showed that circulating autoantibodies against M2 muscarinic receptors (anti-M2R Ab) are associated with decreased cardiac parasympathetic modulation in patients with chronic Chagas disease (CD). Here we investigated whether the exposure of M2R to such antibodies could impair agonist-induced receptor activation, leading to the inhibition of associated signaling pathways. Preincubation of M2R-expressing HEK 293T cells with serum IgG fractions from chagasic patients with cardiovascular dysautonomia, followed by the addition of carbachol, resulted in the attenuation of agonist-induced Gi protein activation and arrestin-2 recruitment. These effects were not mimicked by the corresponding Fab fractions, suggesting that they occur through receptor crosslinking. IgG autoantibodies did not enhance M2R/arrestin interaction or promote M2R internalization, suggesting that their inhibitory effects are not likely a result of short-term receptor regulation. Rather, these immunoglobulins could function as negative allosteric modulators of acetylcholine-mediated responses, thereby contributing to the development of parasympathetic dysfunction in patients with CD.


Subject(s)
Autoantibodies/immunology , Autonomic Nervous System Diseases/immunology , Chagas Disease/immunology , Receptor, Muscarinic M2/immunology , Adult , Aged , Allosteric Regulation , Autoantibodies/metabolism , Autoantibodies/pharmacology , Autonomic Nervous System Diseases/etiology , Autonomic Nervous System Diseases/metabolism , Autonomic Nervous System Diseases/physiopathology , Carbachol/pharmacology , Chagas Disease/complications , Chagas Disease/metabolism , Chagas Disease/physiopathology , Cholinergic Agonists/pharmacology , Female , GTP-Binding Protein alpha Subunits, Gi-Go/metabolism , GTP-Binding Protein alpha Subunits, Gq-G11/metabolism , HEK293 Cells , Heart Rate , Humans , Male , Middle Aged , Receptor, Muscarinic M2/drug effects , Receptor, Muscarinic M2/metabolism , beta-Arrestin 1/metabolism
2.
Clin Immunol ; 203: 154-161, 2019 06.
Article in English | MEDLINE | ID: mdl-31048012

ABSTRACT

T-cell lymphomas include diverse malignancies. They are rare, some have low survival rates and they lack curative therapies. The aim of this work was to assess whether employing the TLR7 agonist imiquimod and the T-cell costimulatory molecule CD40 or the combination of both as adjuvants of a cell lysate vaccine could enhance the antitumor immune response using a murine T-cell lymphoma model. Immunization with LBC-lysate and imiquimod protected almost all vaccinated animals. A specific humoral and a Th1-type cellular immunity were induced in mice that rejected the lymphoma, characterized by an elevated number of CD4 + T-cells and secretion of IFN-γ, locally and systemically. In contrast, CD40 alone or in combination with imiquimod did not improve the protective response obtained with LBC-lysate and imiquimod. Systemic administration of imiquimod proved to have high potential to serve as a vaccine adjuvant for the treatment of T-cell lymphomas and was effective in this immunotherapy model.


Subject(s)
Adjuvants, Immunologic/therapeutic use , Antigens, Neoplasm/immunology , Cancer Vaccines/immunology , Cell Extracts/immunology , Graft vs Tumor Effect/immunology , Imiquimod/therapeutic use , Lymphoma, T-Cell/therapy , Animals , Cell Line, Tumor , Disease Models, Animal , Female , Humans , Imiquimod/pharmacology , Lymphoma, T-Cell/immunology , Mice , Mice, Inbred BALB C , Toll-Like Receptor 7/agonists
3.
Front Immunol ; 8: 286, 2017.
Article in English | MEDLINE | ID: mdl-28360912

ABSTRACT

Extracellular vesicles (EVs), including endosome-derived nanovesicles (exosomes), are involved in cell-cell communication. Through transfer of their molecular contents, extracellular nanovesicles can alter the function of recipient cells. Due to these characteristics, EVs have shown potential as a new alternative for cancer immunotherapy. Tumor exosomes isolated from malignant ascites can activate dendritic cells, thereby priming the immune system to recognize and kill cancer cells. However, a suppressive role on tumor immune response has also been reported, suggesting that the neoplastic stage of carcinogenesis and the microenvironment where tumor cells grow may influence the amount of EVs released by the cell. This neoplastic stage and microenvironment may also impact EVs' components such as proteins and miRNA, determining their biological behavior. Most T-cell lymphomas have an aggressive clinical course and poor prognosis. Consequently, complementary alternative therapies are needed to improve the survival rates achieved with conventional treatments. In this work, we have characterized EVs isolated from ascites of mice bearing a very aggressive murine T-cell lymphoma and have studied their immunogenic properties. Small EVs were isolated by differential centrifugation, ultrafiltration, and ultracentrifugation at 100,000 × g on a sucrose cushion. The EVs were defined as exosomes by their morphology and size analyzed by electron microscopy, their floating density on a sucrose gradient, as well as their expression of endosome marker proteins ALIX, TSG-101; the tetraspanins CD63, CD9, and CD81. In addition, they contain tumor antigens, the marker for malignancy CD24, the heat shock protein HSP-70, and an unusual surface expression of HSP-90 was demonstrated. The administration of EVs isolated from ascites (EVs A) into naïve-syngeneic mice induced both humoral and cellular immune responses that allowed the rejection of subsequent tumor challenges. However, the immunization had no effect on a non-related mammary adenocarcinoma, demonstrating that the immune response elicited was specific and also it induced immune memory. In vitro analysis demonstrated that T-cells from EVs A-immunized mice secrete IFN-γ in response to tumor stimulation. Furthermore, tumor-specific CD4+ and CD8+ IFN-γ secreting cells could be efficiently expanded from mice immunized with EVs A, showing that a T helper 1 response is involved in tumor rejection. Our findings confirm exosomes as promising defined acellular tumor antigens for the development of an antitumor vaccine.

4.
J Immunother ; 36(3): 171-80, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23502764

ABSTRACT

In this study, we assessed the effectiveness of a live, attenuated Salmonella enterica serovar Typhi (S. Typhi) vaccine strain as a cancer immunotherapy in a mouse model of metastatic T-cell lymphoma. EL4 tumor-bearing C57BL/6J mice immunized with S. Typhi strain CVD 915, by injection into the tumor and the draining lymph node areas, displayed a significant decrease in tumor growth, a reduction in the mitotic index (MI) of tumors, a delayed development of palpable lymph node metastases and most importantly improved survival, compared to untreated mice. Besides, complete tumor regression was achieved in a small number of bacteria-treated mice. A successful therapeutic response associated with a significant reduction of tumor mass was evident as early as 5 days after treatment. The administration of Salmonella to tumor-bearing mice promoted early cellular infiltration (mainly neutrophils) within the tumor, and was accompanied by a decreased intratumoral interleukin 10 production as well as by leukocyte expansion in tumor draining lymph nodes. A tumor-specific memory immune response was induced in most of cured animals, as evidenced by the lack of tumor growth after a rechallenge with the same tumor. EL4 cells cultured with live Salmonella failed to proliferate and underwent apoptosis in a dose-dependent, time-dependent, and contact-dependent manner. To our knowledge, these results demonstrate for the first time the efficacy of a S. Typhi vaccine strain as an oncolytic and immunotherapeutic agent against a highly malignant tumor and support the use of S. Typhi-based vaccine strains in cancer therapy.


Subject(s)
Immunotherapy/methods , Lymphoma, T-Cell/therapy , Salmonella typhi/immunology , Typhoid-Paratyphoid Vaccines/therapeutic use , Animals , Apoptosis , Cell Line, Tumor , Cell Proliferation , Female , Interleukin-10/biosynthesis , Lymph Nodes/immunology , Lymphatic Metastasis/prevention & control , Lymphoma, T-Cell/immunology , Lymphoma, T-Cell/microbiology , Male , Mice , Mice, Inbred C57BL , Mice, Nude , Mitotic Index , Typhoid-Paratyphoid Vaccines/immunology , Vaccines, Attenuated/therapeutic use
5.
Vaccine ; 29(4): 728-36, 2011 Jan 17.
Article in English | MEDLINE | ID: mdl-21095252

ABSTRACT

We investigated the use of a live, attenuated Salmonella enterica serovar Typhi vaccine strain as an antitumor immunotherapy. Mice bearing a subcutaneous tumor (LM3 mammary adenocarcinoma) were immunized on three occasions with S. Typhi strain CVD 915 by injection into the tumor, the peritumoral tissue and the draining lymph node areas; this procedure was termed Salmonella multiple treatment (Salmonella MT). Tumor-bearing mice subjected to the Salmonella MT exhibited reduced tumor growth, prolonged survival and reduced incidence of lung metastases, compared to untreated mice. We examined the mechanisms mediating this effect and found that Salmonella MT promoted an antitumor Th1-type response characterized by increased frequencies of IFN-γ-secreting CD4(+) T and CD8(+) T cells with reduction of regulatory T cells in tumor draining lymph nodes. The main cells infiltrating bacteria-treated tumors were activated neutrophils, which can exert an antitumor effect through the secretion of TNF-α. These results demonstrate for the first time the efficacy of an attenuated S. Typhi vaccine strain as a cancer immunotherapeutic agent. By potentiating the host antitumor immune response, this approach could be a powerful adjunct tool for cancer therapy.


Subject(s)
Adenocarcinoma/therapy , Breast Neoplasms/therapy , Cancer Vaccines/immunology , Immunity, Cellular , Immunotherapy/methods , Neutrophil Activation , Salmonella typhi/immunology , Adenocarcinoma/pathology , Animals , Breast Neoplasms/pathology , CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/immunology , Cancer Vaccines/administration & dosage , Disease Models, Animal , Female , Mice , Mice, Inbred BALB C , Neoplasm Metastasis/prevention & control , Survival Analysis , Th1 Cells/immunology , Tumor Necrosis Factor-alpha/metabolism , Vaccination/methods , Vaccines, Attenuated/administration & dosage , Vaccines, Attenuated/immunology
6.
Comun. biol ; 7(3): 247-60, mar. 1989. tab
Article in English | LILACS | ID: lil-74989

ABSTRACT

Se estudió la respuesta inmune inducida por células tumorales, o por extractos de membranas de células tumorales, y la presencia de anticuerpos en el suero de ratones portadores de tumor en un modelo murino. Se demostró la ausencia de anticuerpos en el suero de ratones portadores de tumor. Las células tratadas con Mitomicina C, los extractos de membranas tumorales (TME) y fracciones obtenidos de los mismos (fracción 2) indujeron bajos títulos de anticuerpos específicos cuando se inyectaron en huéspedes singeneicos, mientras que los homogenatos totales de tumor y otras fracciones fueron inefectivas. Los ensayos hechos "in vivo" demostraron que los anticuerpos inducidos no protegían contra las células LB vivas ya que no alteraron el crecimciento del tumor


Subject(s)
Mice , Animals , Male , Female , Immunity, Cellular , Lymphoma/immunology , Mice, Inbred BALB C
7.
Comun. biol ; 7(3): 247-60, mar. 1989. Tab
Article in English | BINACIS | ID: bin-28838

ABSTRACT

Se estudió la respuesta inmune inducida por células tumorales, o por extractos de membranas de células tumorales, y la presencia de anticuerpos en el suero de ratones portadores de tumor en un modelo murino. Se demostró la ausencia de anticuerpos en el suero de ratones portadores de tumor. Las células tratadas con Mitomicina C, los extractos de membranas tumorales (TME) y fracciones obtenidos de los mismos (fracción 2) indujeron bajos títulos de anticuerpos específicos cuando se inyectaron en huéspedes singeneicos, mientras que los homogenatos totales de tumor y otras fracciones fueron inefectivas. Los ensayos hechos "in vivo" demostraron que los anticuerpos inducidos no protegían contra las células LB vivas ya que no alteraron el crecimciento del tumor (AU)


Subject(s)
Mice , Animals , Male , Female , Immunity, Cellular , Lymphoma/immunology , Mice, Inbred BALB C
SELECTION OF CITATIONS
SEARCH DETAIL
...